vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and Marqeta, Inc. (MQ). Click either name above to swap in a different company.

Marqeta, Inc. is the larger business by last-quarter revenue ($172.1M vs $125.2M, roughly 1.4× ARDELYX, INC.). On growth, Marqeta, Inc. posted the faster year-over-year revenue change (26.7% vs 7.8%). Over the past eight quarters, ARDELYX, INC.'s revenue compounded faster (30.8% CAGR vs 20.8%).

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

Marqeta, Inc. operates a cloud-native open API platform for modern card issuing and digital payment processing. Its solutions empower fintech startups, large retailers, and enterprise clients to launch customized physical and virtual payment cards, as well as embedded finance products across global consumer and commercial markets.

ARDX vs MQ — Head-to-Head

Bigger by revenue
MQ
MQ
1.4× larger
MQ
$172.1M
$125.2M
ARDX
Growing faster (revenue YoY)
MQ
MQ
+18.9% gap
MQ
26.7%
7.8%
ARDX
Faster 2-yr revenue CAGR
ARDX
ARDX
Annualised
ARDX
30.8%
20.8%
MQ

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ARDX
ARDX
MQ
MQ
Revenue
$125.2M
$172.1M
Net Profit
Gross Margin
69.7%
Operating Margin
-4.8%
Net Margin
Revenue YoY
7.8%
26.7%
Net Profit YoY
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
MQ
MQ
Q1 26
$125.2M
Q4 25
$125.2M
$172.1M
Q3 25
$110.3M
$163.3M
Q2 25
$97.7M
$150.4M
Q1 25
$74.1M
$139.1M
Q4 24
$116.1M
$135.8M
Q3 24
$98.2M
$128.0M
Q2 24
$73.2M
$125.3M
Net Profit
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
$-407.0K
Q3 25
$-969.0K
$-3.6M
Q2 25
$-19.1M
$-647.0K
Q1 25
$-41.1M
$-8.3M
Q4 24
$4.6M
Q3 24
$-809.0K
$-28.6M
Q2 24
$-16.5M
$119.1M
Gross Margin
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
91.3%
69.7%
Q3 25
96.4%
70.1%
Q2 25
87.3%
69.2%
Q1 25
83.4%
71.0%
Q4 24
84.3%
72.3%
Q3 24
84.0%
70.4%
Q2 24
87.1%
63.3%
Operating Margin
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
4.1%
-4.8%
Q3 25
4.2%
-6.4%
Q2 25
-14.7%
-6.1%
Q1 25
-49.0%
-13.3%
Q4 24
7.0%
-27.6%
Q3 24
2.3%
-33.0%
Q2 24
-18.6%
83.9%
Net Margin
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
-0.3%
Q3 25
-0.9%
-2.2%
Q2 25
-19.5%
-0.4%
Q1 25
-55.5%
-5.9%
Q4 24
4.0%
Q3 24
-0.8%
-22.4%
Q2 24
-22.5%
95.1%
EPS (diluted)
ARDX
ARDX
MQ
MQ
Q1 26
$0.00
Q4 25
$-0.01
Q3 25
$0.00
Q2 25
$-0.08
Q1 25
$-0.17
Q4 24
$0.01
Q3 24
$0.00
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
MQ
MQ
Cash + ST InvestmentsLiquidity on hand
$264.7M
$709.4M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$166.9M
$762.0M
Total Assets
$501.6M
$1.5B
Debt / EquityLower = less leverage
1.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
MQ
MQ
Q1 26
$264.7M
Q4 25
$68.0M
$709.4M
Q3 25
$42.7M
$747.2M
Q2 25
$90.0M
$732.7M
Q1 25
$30.8M
$830.9M
Q4 24
$64.9M
$923.0M
Q3 24
$47.4M
$886.4M
Q2 24
$41.9M
$924.7M
Total Debt
ARDX
ARDX
MQ
MQ
Q1 26
$202.8M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
MQ
MQ
Q1 26
$166.9M
Q4 25
$166.9M
$762.0M
Q3 25
$154.3M
$839.2M
Q2 25
$139.5M
$843.4M
Q1 25
$145.7M
$987.3M
Q4 24
$173.3M
$1.1B
Q3 24
$158.3M
$1.1B
Q2 24
$147.0M
$1.1B
Total Assets
ARDX
ARDX
MQ
MQ
Q1 26
$501.6M
Q4 25
$501.6M
$1.5B
Q3 25
$486.2M
$1.5B
Q2 25
$466.8M
$1.2B
Q1 25
$410.2M
$1.3B
Q4 24
$435.8M
$1.5B
Q3 24
$367.9M
$1.4B
Q2 24
$343.5M
$1.5B
Debt / Equity
ARDX
ARDX
MQ
MQ
Q1 26
1.21×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
MQ
MQ
Operating Cash FlowLast quarter
$53.3M
Free Cash FlowOCF − Capex
$53.2M
FCF MarginFCF / Revenue
30.9%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$160.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
$21.0M
$53.3M
Q3 25
$365.0K
$86.8M
Q2 25
$-25.3M
$12.5M
Q1 25
$-38.5M
$10.0M
Q4 24
$9.8M
$24.8M
Q3 24
$501.0K
$7.3M
Q2 24
$-19.4M
$25.7M
Free Cash Flow
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
$20.6M
$53.2M
Q3 25
$209.0K
$86.4M
Q2 25
$-26.0M
$12.2M
Q1 25
$-38.8M
$8.7M
Q4 24
$9.2M
$24.7M
Q3 24
$364.0K
$7.1M
Q2 24
$-19.5M
$24.7M
FCF Margin
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
16.4%
30.9%
Q3 25
0.2%
52.9%
Q2 25
-26.6%
8.1%
Q1 25
-52.3%
6.3%
Q4 24
7.9%
18.2%
Q3 24
0.4%
5.5%
Q2 24
-26.7%
19.7%
Capex Intensity
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
0.3%
0.1%
Q3 25
0.1%
0.2%
Q2 25
0.7%
0.2%
Q1 25
0.4%
0.9%
Q4 24
0.5%
0.0%
Q3 24
0.1%
0.1%
Q2 24
0.2%
0.8%
Cash Conversion
ARDX
ARDX
MQ
MQ
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
2.11×
Q3 24
Q2 24
0.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$86.6M69%
XPHOZAH$27.8M22%
Product supply revenue$9.4M8%
Non-cash royalty revenue related to the sale of future royalties$1.4M1%
Licensing revenue$23.0K0%

MQ
MQ

Platform Service Revenue Net$163.4M95%
Other Services Revenue$8.8M5%

Related Comparisons